Discovery of novel small molecule inhibitors of cardiac hypertrophy using high throughput, high content imaging

Journal of Molecular and Cellular Cardiology

Volumn 97, Issue , 2016, Pages 106-113

  Reid, Brian G ^a   Stratton, Matthew S ^b   Bowers, Samantha ^a   Cavasin, Maria A ^b   Demos Davies, Kimberley M ^b   Susano, Isidro ^a   McKinsey, Timothy A ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Cardiomyocyte; High content; High throughput; Hypertrophy; Screening; Small molecule

Indexed keywords

ARTESUNATE; ATOMOXETINE; ATRIAL NATRIURETIC FACTOR; BICALUTAMIDE; BROMOCRIPTINE; CARDIOVASCULAR AGENT; CLEMIZOLE; CLOZAPINE; DOXEPIN; ESCITALOPRAM; ETICLOPRIDE; FLUVOXAMINE; IMIPRAMINE; ISOTRETINOIN; LABETALOL; LOXAPINE; MEBEVERINE; MELENGESTROL; NEFAZODONE; NORTRIPTYLINE; OXYMETHOLONE; PEROSPIRONE; PHENELZINE; PHENYLEPHRINE; PHORBOL 13 ACETATE 12 MYRISTATE; PROFENAMINE; RETINOIC ACID; SECURININE; TIRATRICOL; UNINDEXED DRUG; MOLECULAR LIBRARY;

ADULT; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CARDIAC MUSCLE CELL; CELL SIZE; CONTROLLED STUDY; DRUG SCREENING; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEWBORN; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VENTRICULAR MYOCYTE; ANIMAL; CARDIOMEGALY; CELL CULTURE; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; HEART VENTRICLE REMODELING; HEMODYNAMICS; HIGH THROUGHPUT SCREENING; METABOLISM; MOLECULAR IMAGING; MOLECULAR LIBRARY; PROCEDURES; REPRODUCIBILITY;

ANIMALS; CARDIOMEGALY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HEMODYNAMICS; HIGH-THROUGHPUT SCREENING ASSAYS; MALE; MICE; MOLECULAR IMAGING; MYOCYTES, CARDIAC; RATS; REPRODUCIBILITY OF RESULTS; SMALL MOLECULE LIBRARIES; VENTRICULAR REMODELING;

EID: 84969242817     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2016.04.015     Document Type: Article

References (37)

1. Hughes J.P., Rees S., Kalindjian S.B., Philpott K.L. Principles of early drug discovery. Br. J. Pharmacol. 2011, 162:1239-1249.
2. Pereira D.A., Williams J.A. Origin and evolution of high throughput screening. Br. J. Pharmacol. 2007, 152:53-61.
3. Mayr L.M., Bojanic D. Novel trends in high-throughput screening. Curr. Opin. Pharmacol. 2009, 9:580-588.
4. Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., Borden W.B., et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125:e2-e220.
5. Devereux R.B., Wachtell K., Gerdts E., Boman K., Nieminen M.S., Papademetriou V., et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004, 292:2350-2356.
6. Gardin J.M., Lauer M.S. Left ventricular hypertrophy: the next treatable, silent killer?. JAMA 2004, 292:2396-2398.
7. Hill J.A., Olson E.N. Cardiac plasticity. N. Engl. J. Med. 2008, 358:1370-1380.
8. Braunwald E. Research advances in heart failure: a compendium. Circ. Res. 2013, 113:633-645.
9. McKinsey T.A., Kass D.A. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat. Rev. Drug Discov. 2007, 6:617-635.
10. Long C.S., Henrich C.J., Simpson P.C. A growth factor for cardiac myocytes is produced by cardiac nonmyocytes. Cell. Regul. 1991, 2:1081-1095.
11. Spiltoir J.I., Stratton M.S., Cavasin M.A., Demos-Davies K., Reid B.G., Qi J., et al. BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. J. Mol. Cell. Cardiol. 2013, 63:175-179.
12. Zhang J.H., Chung T.D., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 1999, 4:67-73.
13. Antos C.L., McKinsey T.A., Dreitz M., Hollingsworth L.M., Zhang C.L., Schreiber K., et al. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J. Biol. Chem. 2003, 278:28930-28937.
14. Hess K.M., Goad J.A., Arguin P.M. Intravenous artesunate for the treatment of severe malaria. Ann. Pharmacother. 2010, 44:1250-1258.
15. Desai A.S., McMurray J.J., Packer M., Swedberg K., Rouleau J.L., Chen F., et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur. Heart J. 2015, 36:1990-1997.
16. McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 2014, 371:993-1004.
17. Packer M., McMurray J.J., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015, 131:54-61.
18. Eichhorn E.J., Bristow M.R. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 1996, 94:2285-2296.
19. Jentzsch C., Leierseder S., Loyer X., Flohrschutz I., Sassi Y., Hartmann D., et al. A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J. Mol. Cell. Cardiol. 2012, 52:13-20.
20. Ryall K.A., Bezzerides V.J., Rosenzweig A., Saucerman J.J. Phenotypic screen quantifying differential regulation of cardiac myocyte hypertrophy identifies CITED4 regulation of myocyte elongation. J. Mol. Cell. Cardiol. 2014, 72:74-84.
21. Carlson C., Koonce C., Aoyama N., Einhorn S., Fiene S., Thompson A., et al. Phenotypic screening with human iPS cell-derived cardiomyocytes: HTS-compatible assays for interrogating cardiac hypertrophy. J. Biomol. Screen. 2013, 18:1203-1211.
22. Foldes G., Matsa E., Kriston-Vizi J., Leja T., Amisten S., Kolker L., et al. Aberrant α-adrenergic hypertrophic response in cardiomyocytes from human induced pluripotent cells. Stem Cell Rep. 2014, 3:905-914.
23. Force T., Kolaja K.L. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat. Rev. Drug Discov. 2011, 10:111-126.
24. Kagiyama S., Eguchi S., Frank G.D., Inagami T., Zhang Y.C., Phillips M.I. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 2002, 106:909-912.
25. McMullen J.R., Sherwood M.C., Tarnavski O., Zhang L., Dorfman A.L., Shioi T., et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004, 109:3050-3055.
26. Nakagami H., Jensen K.S., Liao J.K. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann. Med. 2003, 35:398-403.
27. Shioi T., McMullen J.R., Tarnavski O., Converso K., Sherwood M.C., Manning W.J., et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003, 107:1664-1670.
28. Shen B. A new golden age of natural products drug discovery. Cell 2015, 163:1297-1300.
29. Gu Y., Wang X., Wang X., Yuan M., Wu G., Hu J., et al. Artemisinin attenuates post-infarct myocardial remodeling by down-regulating the NF-κB pathway. Tohoku J. Exp. Med. 2012, 227:161-170.
30. Xiong Z., Sun G., Zhu C., Cheng B., Zhang C., Ma Y., et al. Artemisinin, an anti-malarial agent, inhibits rat cardiac hypertrophy via inhibition of NF-κB signaling. Eur. J. Pharmacol. 2010, 649:277-284.
31. Guo Z. Artemisinin anti-malarial drugs in China. Acta Pharm. Sin. B 2016, 6:115-124.
32. Lee I.S., Ryu D.K., Lim J., Cho S., Kang B.Y., Choi H.J. Artesunate activates Nrf2 pathway-driven anti-inflammatory potential through ERK signaling in microglial BV2 cells. Neurosci. Lett. 2012, 509:17-21.
33. Li Y., Wang S., Wang Y., Zhou C., Chen G., Shen W., et al. Inhibitory effect of the antimalarial agent artesunate on collagen-induced arthritis in rats through nuclear factor κ B and mitogen-activated protein kinase signaling pathway. Transl. Res. 2013, 161:89-98.
34. Cominacini L., Mozzini C., Garbin U., Pasini A., Stranieri C., Solani E., et al. Endoplasmic reticulum stress and Nrf2 signaling in cardiovascular diseases. Free Radic. Biol. Med. 2015, 88:233-242.
35. Kehat I., Molkentin J.D. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 2010, 122:2727-2735.
36. Pagel-Langenickel I., Buttgereit J., Bader M., Langenickel T.H. Natriuretic peptide receptor B signaling in the cardiovascular system: protection from cardiac hypertrophy. J. Mol. Med. (Berl.) 2007, 85:797-810.
37. Minguet J., Sutton G., Ferrero C., Gomez T., Bramlage P. LCZ696: a new paradigm for the treatment of heart failure?. Expert. Opin. Pharmacother. 2015, 16:435-446.